论文部分内容阅读
目的探讨厄贝沙坦联合倍他乐克联合应用治疗慢性充血性心力衰竭的临床疗效。方法选择80例慢性充血性心衰竭住院患者,随机分为治疗组(40例)和对照组(40例),在心力衰竭常规治疗的基础上,治疗组给予倍他克6.25mg/d与厄贝坦75mg/d。结果治疗16周后治疗组心力衰竭患者心功能分级改善显著,总有效率95%,无效2例占5%;对照组总有效率70%,无效12例占30%。两组比较总有效率有差异显著(p<0.05)。结论厄贝沙坦联合倍他乐克治疗慢性充血性心力衰竭能显著提高临床疗效,并且未增加副反应。
Objective To investigate the clinical efficacy of irbesartan combined with Betaloc in the treatment of chronic congestive heart failure. Methods Eighty hospitalized patients with chronic congestive heart failure were randomly divided into treatment group (40 cases) and control group (40 cases). On the basis of conventional treatment of heart failure, the treatment group was treated with Betaloc 6.25 mg / Betan 75mg / d. Results After 16 weeks of treatment, heart function scores of patients in treatment group improved significantly. The total effective rate was 95% and invalid rate was 2%. The total effective rate was 70% in control group and 30% in 12 cases. The total effective rate was significantly different between the two groups (p <0.05). Conclusion Irbesartan combined with Betaloc in the treatment of chronic congestive heart failure can significantly improve the clinical efficacy, and did not increase the side effects.